Literature DB >> 2952467

Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD.

M Leeman, P Lejeune, C Melot, R Naeije.   

Abstract

Hemodynamics, blood gas values, and lung mechanics were investigated in 19 patients with decompensated COPD before and 30 and 60 minutes after a slow (15 minute) intravenous administration of 3 mg/kg enoximone (MDL 17,043). In the first 11 patients who were spontaneously breathing, enoximone significantly decreased pulmonary arterial wedge pressure, right atrial pressure, mean systemic arterial pressure, and mean pulmonary arterial pressure. Cardiac output remained unchanged, while heart rate increased slightly. Lung resistance decreased and dynamic lung compliance increased. Blood gas values remained unchanged. Similar effects were observed in the next eight patients who were artificially ventilated, except for an increase in cardiac output. These results show that enoximone has bronchodilating and pulmonary vasodilating properties.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952467     DOI: 10.1378/chest.91.5.662

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

2.  A pathophysiological role of PDE3 in allergic airway inflammation.

Authors:  Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan
Journal:  JCI Insight       Date:  2018-01-25

Review 3.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 4.  Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.

Authors:  I P Hall
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

Review 5.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 6.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

7.  PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells.

Authors:  Jan Beute; Keerthana Ganesh; Hedwika Nastiti; Robin Hoogenboom; Vivica Bos; Jelle Folkerts; Marco W J Schreurs; Steve Hockman; Rudi W Hendriks; Alex KleinJan
Journal:  Front Pharmacol       Date:  2020-05-01       Impact factor: 5.810

8.  PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia.

Authors:  Jan Beute; Pieter Boermans; Bart Benraad; Jan Telman; Zuzana Diamant; Alex KleinJan
Journal:  Exp Lung Res       Date:  2021-02-05       Impact factor: 2.459

9.  Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report.

Authors:  Jan Beute; Pieter Boermans; Alex KleinJan
Journal:  Can Respir J       Date:  2021-11-01       Impact factor: 2.409

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.